NCT07012746尚未招募不适用
A Randomized, Double-Blind, Placebo-Parallel-Controlled Clinical Trial to Explore the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing Loss
Yilai Shu1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年6月7日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Safety of TJ0113 capsule in the treatment of patients with age-related hearing loss
研究概览
简要总结
The purpose of this study is to explore the safety and efficacy of TJ0113 capsules in patients with age-related hearing loss.
详细描述
The main purpose of this clinical trial is to explore the safety of TJ0113 capsules in patients with age-related hearing loss; the secondary purpose is to explore the effectiveness; and the exploratory purpose is to exploring changes in muscle strength, depression degree, cognition, and biomarkers after TJ0113 capsule treatment in patients with age-related hearing loss. Approximately 60 subjects (aged from 65~75) will be enrolled in this study according to the randomization and drug randomization tables both of which were generated by computer. The successfully screened subjects were randomly assigned to the 1:1 TJ0113 capsule group (n=30) and placebo group (n=30).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 65 Years 至 75 Years（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subjects voluntarily participate in the clinical trial, sign the informed consent form, understand and follow the protocol, and fully understand the test content, process and possible adverse reactions.
- •Age between 65 and 80 years (including the critical value)
- •A diagnosis of symmetrical sensorineural deafness (SNHL) with a history of> 3 months (binaural threshold difference in mean PTA frequency <15 dB HL), the PTA level should be between moderate (> 35dB) and severe (<80dB) hearing loss
- •Hearing aids have not been used, or otherwise, it should be used regularly for more than 3 years and stopped for 3 months before enrollment.
- •Subjects and their partners had no birth plan, sperm or egg donation plans from the screening period until within 6 months after the end of the trial and would voluntarily take effective contraception (e. g. abstinence, condoms, etc.). Male subjects should agree to avoid sperm donation within 6 months from the start of administration until cessation of study treatment. Female subjects should be menopausal (over 24 months).
排除标准
- •The presence of implants in the study ear (such as cochlear implant, artificial hearing bone, etc.);
- •Suffering from acute otitis media or other ear infection within the previous 3 months or previous chronic suppurative otitis media or tympanic membrane perforation, or with conductive deafness, previous history of ear trauma or surgery, combined middle ear or inner ear malformation, otosclerosis, Meniere's disease, sudden deafness and no recovery of hearing, all of which will impact results explained.
- •Patients with sensorineural deafness caused by non-aging factors (e. g., hereditary deafness, congenital deafness, drug-induced deafness, noise deafness, neurosyphilis, severe retrocochlear lesions or organic lesions), and unilateral deafness
- •Occupation that is sensitive to sound: musician, conductor, music teacher, etc.
- •Use headphones at high volume or frequent exposure to noise in previous work or life;
- •History of alcohol or drug dependence / drug abuse in the last 1 year;
- •Positive pregnancy test at screening or at the baseline visit, pregnant, lactating, or planned to become pregnant during the trial
- •7.Failure to swallow oral medication, or, according to the investigator, any conditions that may significantly affect the absorption, distribution, metabolism and excretion of the drug, or that may pose a hazard to the subjects participating in this trial; 9.People who currently taking drugs that can improve symptoms such as dementia and depression 10.Subjects with a severe or unstable systemic disease, such as serious congenital disease, blood disease, endocrine disease, nerve or nervous system disease, end-stage disease, head and neck tumor radiotherapy and chemotherapy history, major surgical treatment, psychological disorders (severe insomnia, severe depression, severe anxiety, etc. diagnosed within the previous 90 days ) or history and clinical significance of abnormal baseline laboratory values, such as hepatic insufficiency (alanine transaminase (ALT) and / or alanine transaminase (AST) is 2 times above the upper limit of the reference range, or renal insufficiency (creatinine clearance Ccr <30 mL/min), or history of malignant tumors and the detection results of tumor markers during the screening period have clinical significance, or unsuitable participants, as judged by the investigator; 11.Subjects suffering from any one of the following heart diseases: a. having uncontrolled or serious cardiovascular and cerebrovascular disease, including the development of grade II ( New York Heart Association, NYHA) or above congestive heart failure, unstable angina, acute myocardial infarction within 6 months before the first drug administration, or cardiac arrhythmias requiring treatment at screening; With b. hypertension (systolic pressure≥ 160mmHg and / or diastolic v≥ 100mmHg), and after the combination of two or more antihypertensive drugs can not be reduced to the normal range; or c.with a history of clinically significant ECG abnormalities, the QRS time was> 120ms, Long QT syndrome: QTc interval> 450ms in male or QTc interval> 470ms in female.
- •12.Participated in a clinical study involving the administration, device, or surgery of the study drug (new chemical entity) within 90 days or 5 half-lives (whichever is longer) 13.Patients with a previous history of hepatitis B, or any of the following indicators are positive at screening: hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or treponema pallidum antibody.
- •14.The subject is not fit to participate in the study if the investigator considers. Or the subject could not participate in the trial for his own reasons, or the behavior subject may interfere with treatment, study or interpretation of results (e. g., previous treatment with high-dose aminoglycosides).
研究组 & 干预措施
TJ0113 group
Experimental
Participants will be treated with TJ0113 capsule 200 mg daily for up to 24 weeks
干预措施: TJ0113 capsules (Drug)
Placebo group
Placebo Comparator
Participants will be treated with a placebo 200 mg daily for up to 24 weeks
干预措施: Placebo capsules (Drug)
结局指标
主要结局
Safety of TJ0113 capsule in the treatment of patients with age-related hearing loss
时间窗: Baseline, weeks 1, 4, 12, 24, and 1 week after discontinuation
Incidence of adverse events in each group
次要结局
- Speech Intelligibility - Word Recognition in Quiet and Noise(From baseline to 4, 12 ,24 weeks)
- Pure Tone Audiometry (PTA)(From baseline to 4, 12 ,24 weeks)
- Individual's health-related quality of life (HRQOL)(From baseline to 4, 12 ,24 weeks)
研究者
Yilai Shu
Principal Investigator
Eye & ENT Hospital of Fudan University
研究点 (1)
Loading locations...
相似试验
已完成
3 期
JT001 (VV116) for the Treatment of COVID-19Mild to Moderate COVID-19NCT05582629Shanghai Vinnerna Biosciences Co., Ltd.1,369
终止
2 期
JT001 (VV116) for the Early Treatment of COVID-19Mild to Moderate COVID-19NCT05242042Shanghai JunTop Biosciences Co., LTD381
Unknown
2 期
YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes MellitusDiabetic ComplicationNCT01836172Han Wha Pharma Co., Ltd.136
已完成
1 期
A Study of JNJ-77242113 in Healthy Japanese and Chinese ParticipantsHealthyNCT05062200Janssen Pharmaceutical K.K.36
撤回
1 期
A Study of JNJ-75105186 in Healthy Japanese and Chinese ParticipantsHealthyNCT05159128Janssen Pharmaceutical K.K.